Urban living is back in fashion after a brief move away from cities during the pandemic
Key focus on enabling prioritization and rapid progression of pipeline programs through to clinical proof-of-concept, a key milestone for value creation
Sosei Heptares will use the collaboration to ‘turbo charge’ its internal discovery and early clinical development strategy, and unlock the full potential of its world-leading GPCR-based drug discovery and development platform
Weatherden is a pioneering clinical development consulting group trusted by biopharma, venture capital funds, startups, spin-outs and nonprofit organizations to deliver better drugs, faster
TOKYO and CAMBRIDGE, United Kingdom, April 26, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) today announces a strategic collaboration with Weatherden, a pioneering clinical development consulting group. The collaboration aims to build upon Sosei Heptares’ world-leading G protein-coupled receptor (GPCR) structure-based drug design (SBDD) platform and expertise and Weatherden’s translational medicine and drug development expertise to create an agile operating model supported by best-in-class drug discovery and development teams. The goal being to accelerate the prioritization and progression of multiple pipeline programs through Phase 1b/2a trials to establish clinical proof-of-concept. This stage represents a key value inflection point that Sosei Heptares intends to achieve as part of its evolution to become a multi-program, clinical-stage biotech company.
By leveraging Weatherden’s extensive experience, scientific expertise and data driven approach, together with its commercial focus on pharmaceutical asset evaluation and development, Sosei Heptares is bringing together the operational and technical expertise needed to enable a ‘venture-like’ capital allocation approach to pipeline development.
In this way, the Company aims to optimize decision-making and value generation by:
creating new, efficient drug discovery and development pathways,
accelerating the translation of its world-leading science into life-changing therapeutics for patients, and
maximizing partnering transaction opportunities by taking selected in-house programs to clinical proof-of-concept stage
“Sosei Heptares’ world-leading platform gives us access to more GPCR drug discovery opportunities than can be tackled in a lifetime. It is essential to our long-term success that we continually enhance our ability to identify and prioritize these opportunities to optimize value creation for patients and shareholders,” said Chris Cargill, President and CEO of Sosei Heptares. “Sosei Heptares has an exceptional opportunity to embed agile, program-centric operating practices across its discovery and early development activities to be as efficient and productive as possible. We are uniquely positioned to do this because our expanding discovery platform has the potential to produce an abundance of new, high-quality drug candidates to which VC-like capital allocation and a ‘quick win/fast fail’ approach can be applied.
“By focusing on translational medicine, which we see as the R&D ‘sweet spot’ for investment in new programs, we will rigorously ‘test the hypothesis’ earlier during more economical phases of drug development to optimize our pipeline decisions going forward. This agile approach will allow us to rapidly advance only programs we believe have the best probability of success through to proof-of-concept, with strong product profiles, and the potential to become the life-changing therapeutics of the future.
“We are excited to be partnering with Weatherden, whose experience across the early development stage, and particularly in translational medicine, complements Sosei Heptares’ existing expertise in early-stage drug discovery. We look forward to a dynamic, and productive partnership as we look to maximize the value from our extensive pipeline and support major partnering transaction opportunities to fund our continued expansion and maximize returns.”
Emma Tinsley, CEO of Weatherden, added: “The sheer scale of the GPCR opportunity alongside Sosei Heptares’ ability to exploit this area makes this collaboration extremely exciting. Our track record in efficiently designing and delivering Phase 1b/2a clinical trials will be of great benefit to support Sosei Heptares in its transition to a multi clinical-stage asset company. We are looking forward to working closely with the Sosei Heptares team to enhance its pipeline development approach. We are confident that by combining our skills and experience, the Company will be well positioned to drive its programs forward efficiently and effectively, and to fully realise the potential of its innovative technology and accelerate the progress of much needed medicines for patients worldwide.”
In March 2022, Sosei Heptares announced changes to its senior leadership designed to support its new growth strategy and the enhanced focus on translational medicine. The Company has already made progress towards this goal through the addition of expertise internally, and through entering collaborations with innovative technology companies. This has already yielded novel targets and new ways of exploring and exploiting the Company’s platform and this latest collaboration with Weatherden provides another important element in maximizing the value of these advances.
The strategic collaboration with Weatherden will initially focus on supporting the translational medicine and clinical development plans for the Company’s H4 antagonist and GPR52 agonist programs. There is no change to the Company’s forecast R&D expense guidance for FY2022.
About Sosei Heptares We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging biotechnology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
For more information, please visit https://soseiheptares.com/ LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco
About Weatherden Weatherden is a pioneering clinical development consulting group trusted by biopharma, funds, startups, spin-outs and nonprofits. We advise companies from the earliest stages on scientific strategy, translational medicine and clinical development, through to diligence preparation and support for M&A. Our focus is on de-risking programs early, optimizing clinical, regulatory, and commercial pathways from discovery to market and accelerating the translation of novel science into life-changing medicines for patients.
Blending more than 750 years’ experience across the industry, we are invested in our clients’ success, motivated by the opportunity to rapidly improve the chances for breakthrough therapies to tackle unmet clinical need. Combining an agile biotech mindset with the proven expertise of pharmaceutical drug discovery and development, we work at the cutting edge of clinical, scientific and technological innovation to maximize value, enhance patient outcomes and simplify paths to market.
For more information, please visit: https://weatherden.co.uk/
Sosei Heptares – Media and Investor Relations Japan Hironoshin Nomura, Chief Financial Officer +81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures +81 (0)3 5210 3399 | IR@SoseiHeptares.com
United Kingdom Candelle Chong, SVP Investor Relations and Corporate Strategy +44 (0)1223 949390 | IR@SoseiHeptares.com
MEDiSTRAVA Consulting (for International Media) Mark Swallow, David Dible, Eleanor Perkin +44 (0)203 928 6900| SoseiHeptares@medistrava.com
Weatherden Emma Tinsley, Chief Executive Officer +44 (0)333 050 9157 | services@weatherden.co.uk
Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Used car buyers face years of shortages as Chinese Covid lockdowns and a dearth of microchips hammer manufacturers, Auto Trader has warned.
The dollar edged lower on Friday on its way to a second-straight weekly decline as traders pared expectations for U.S. Federal Reserve interest rate hikes and as improving inflation and consumer spending data eased recession fears. On a weekly basis, it was down 1.24%, following a 1.45% decline the previous week. The "Fed is fully priced and expectations for rate hikes later in the year may be subject to revision if the economy slows more quickly than expected," they said.
Global Market for Metal Finishing Chemicals Global Market for Metal Finishing Chemicals Dublin, May 26, 2022 (GLOBE NEWSWIRE) -- The "Metal Finishing Chemicals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Metal Finishing Chemicals Market to Reach $11.5 Billion by 2026 The global market for Metal Finishing Chemicals estimated at US$9 Billion in the year 2020, is projected to reach a revised size of US$11.5 Billion by 2026, growing at a
A strong dollar typically weighs on oil prices because it makes the commodity more expensive for holders of other currencies, potentially hurting demand for crude. MUFG expects the divergence between the dollar and broader commodities besides oil to continue.
Wall Street stocks rose for a second straight session Thursday on a mixed day for global equities, while China's premier offered an unusually stark warning as the country's zero-Covid strategy bites into growth.
ATHENS (Reuters) -Aegean Airlines, Greece's largest carrier, reported a smaller loss in the first quarter compared to the same period a year earlier, as passenger traffic recovered from pandemic travel restrictions. Aegean, a member of the Star Alliance airlines group, reported a net loss of 38.5 million euros ($41.22 million) in the January-to-March period compared to a loss of 44.5 million in the first quarter of 2021. Chief Executive Dimitris Gerogiannis said the airline managed to shrink its loss in the first quarter despite the doubling of fuel costs compared to 2019 and the prevalence of the Omicron variant.
The growth in the Global Agricultural Films Market is expected to be driven by increasing demand for agricultural output and growing Controlled Agricultural Practices. Market Lifecycle Stage.New York, May 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Agricultural Films Market - A Global and Regional Analysis: Focus on Product, Application, Supply Chain, and Country-Wise Analysis - Analysis and Forecast, 2022-2027" - https://www.reportlinker.com/p06281032/?utm
The public offer was admitted on April 29 after Italy's MediaForEurope, controlled by the family of former Italian Prime Minister Silvio Berlusconi, previously announced the intention to buy out minority holdings in its Spanish subsidiary. MFE, previously known as Mediaset, said it would offer 4.5 of its ordinary A shares and 1.860 euros in cash for each Mediaset Espana share.
The new figures come days after the company told shareholders it had picked its preferred suitor as part of a takeover battle.
Kwasi Kwarteng has asked National Grid to bolster electricity supplies using coal this winter amid concerns Russia’s supply of gas to Europe will be cut off.
Missguided is lining up administrators as the fast-fashion firm teeters on the brink of collapse after being issued with a winding-up petition by creditors.
More than one in four adults in the UK are thinking about what they can do to improve the energy efficiency of their homes.
Britain lagging behind in race to build vital large-scale and local battery factories
The budget retailer’s shares have been suffering over the last year.
It came as Asda posted a plunge in sales for the first quarter of the year.
The average price of using a public rapid charger in the UK increased from 36.7p per kilowatt hour in September 2021 to 44.6p per kWh this month.
The new figures come days after the company told shareholders it had picked its preferred suitor as part of a takeover battle.
Patrick Drahi’s Altice increased its holding from 12.1% to 18% in December last year.
Major players in the automotive heat shield market are Autoneum, Carcoustics, Dana Incorporated, Elringklinger, Lydall, Morgan Advanced Materials, Tenneco, UGN, Covpress, DuPont, Federal-Mogul Corporation, and Happich.New York, May 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automotive Heat Shield Global Market Report 2022" - https://www.reportlinker.com/p06280932/?utm_source=GNW The global automotive heat shield market is expected to grow from $11.82 billi
LONDON (Reuters) -British finance minister Rishi Sunak said on Thursday that high inflation was causing acute distress to Britons, and that he expected the Bank of England to take "decisive action" to get prices back under control. British consumer price inflation hit a 40-year high of 9.0% in April, and the Bank of England has forecast it will reach double digits by the end of this year when regulated energy prices are set to rise by a further 40%. Sunak said the BoE's independence to set interest rates was the best way to ensure inflation returned to its 2% target, following criticism from some members of his party that the central bank has been too slow to raise rates.